News & Events Press Releases Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress May 22, 2023 Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates Mar 28, 2023 Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction Sep 29, 2022 Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer May 25, 2022 Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases Mar 8, 2022 Upcoming Events June 2-6, 2023 American Society of Clinical Oncology (ASCO) Annual Meeting 2023 May 20-23, 2023 European Society of Cardiology’s Heart Failure (ESC-HF) Congress 2023 April 14-19, 2023 American Association for Cancer Research (AACR) Annual Meeting 2023 Past Events March 6–8, 2023 Cowen 43rd Annual Health Care Conference Tuesday, June 21, 2022 11:00 A.M. EDT Baird Webcast: Baird's Biotech Discovery Series January 10, 2022 at 7:00 am EDT H.C. Wainwright 24th Annual Global Investment Virtual Conference
Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress May 22, 2023
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates Mar 28, 2023
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction Sep 29, 2022
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer May 25, 2022
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases Mar 8, 2022
